Je was op zoek naar: mielosupresie (Roemeens - Engels)

mielosupresie
myelosuppression

mielosupresie/neutropenie
myelosuppression/neutropenia

basiliximab nu provoacă mielosupresie.
basiliximab does not cause myelosuppression.

toţi pacienţii au prezentat mielosupresie marcată.
all patients experienced a profound myelosuppression.

infecţii şi afecţiuni maligne care determină mielosupresie
infections and malignancies causing myelosuppression

poate apărea o mielosupresie în formă severă.
severe myelosuppression may occur.

mielosupresie (inclusiv anemie, neutropenie, trombocitopenie)
myelosuppression (including anaemia, neutropaenia, thrombocytopaenia)

nu s-au semnalat manifestări de mielosupresie cumulativă.
no evidence of cumulative myelosuppression was observed.

insuficienţă renală sau hepatică severă şi mielosupresie severă
severe renal or hepatic failure and severe myelosuppression

exemplu tromboflebită, embolie pulmonară) sau mielosupresie severă.
pulmonary embolism) or severe myelosuppression.

majoritatea pacienţilor au continuat tratamentul fără dovezi ulterioare de mielosupresie.
most patients continued treatment without further evidence of myelosuppression.

principalul efect toxic se manifestă la nivelul măduvei hematogene, determinând mielosupresie.
the principal toxic effect is on the bone marrow, resulting in myelosuppression.

1 pe baza evaluărilor de laborator: grad maximal de mielosupresie (populație tratată)
1 based on laboratory assessments: maximal degree of myelosuppression (treated population)

64 reacţii adverse importante mielosupresie: tratamentul cu dasatinib este asociat cu anemie, neutropenie şi trombocitopenie.
important adverse reactions myelosuppression: treatment with dasatinib is associated with anaemia, neutropenia and thrombocytopenia.

dozele repetate, mai mari decât doza recomandată, sunt asociate cu mielosupresie crescută, inclusiv leucopenie, anemie şi trombocitopenie.
higher than recommended repeat doses are associated with increased myelosuppression including leukopenia, anaemia and thrombocytopenia.

pacienţii trataţi cu pixuvri pot prezenta mielosupresie (neutropenie, leucopenie, anemie, trombocitopenie şi limfopenie), neutropenia fiind manifestarea predominantă.
patients treated with pixuvri are likely to experience myelosuppression (neutropenia, leukopenia, anaemia, thrombocytopenia, and lymphopenia) with the predominant manifestation being neutropenia.

de obicei mielosupresia este forma de toxicitate care impune limitarea dozei.
myelosuppression is usually the dose-limiting toxicity.